
206. ASCO 2026 - Part 1
ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-

Hosted by Michael Fernando and Josh Hurwitz · 🇺🇸 US · EN · 223 episodes
Established thought leaders with verified media credentials.
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Michael Fernando and Josh Hurwitz hosts Oncology for the Inquisitive Mind, a health show with 223 episodes published.

ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-

This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer

This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an imp

This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy i

Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. Whi

On today's episode, Josh and Michael "advance" in their ongoing GI journey, as Michael continuously insists on saying, to discuss advanced gastric and GOJ cancer. Historically, an orphan disease with a very poor prognosi

This week, as we enter our 200th episode, Michael and Josh continue their journey through the alimentary canal, exploring the world of stomach cancer. Gastric cancer has been notoriously difficult to treat, with a thirty

Good therapeutic options for metastatic colorectal cancer are limited after the fluoropyrimidine-based options are exhausted. This week, we explore the role of trifluridine-tipiracil (Lonsurf) and bevacizumab (VEGF inhib

Today's episode, like several of the greatest cult classics, comes a bit earlier than anticipated. Before we wrap up our epic recap of the colorectal space, we will give you a little taster of our UGI series with a look

Metastatic Colorectal Cancer has a dearth of targetable mutations that have effective outcomes. This week, Michael and Josh see whether the wonder drug (trastruzumab deruxtecan) works in HER2-expressing colorectal cancer

UPDATED WITH CORRECT AUDIO While Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mut

Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instabili

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it mor

Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including

The DYNAMIC duo are back, with Michael climbing the "Everest" of oncology and exploring the role of CTDNA in stage two colorectal cancer. Josh has the easier job of exploring neoadjuvant immunotherapy (ipilimumab and niv

This week, we explore early colorectal cancer. Maybe it’s just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment

This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a f

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, i

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium wi
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.





Oncology for the Inquisitive Mind has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
Oncology for the Inquisitive Mind is hosted by Michael Fernando and Josh Hurwitz. The show is categorised under health (fitness) and has published 223 episodes.
Oncology for the Inquisitive Mind has published 223 episodes.
Oncology for the Inquisitive Mind regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
Oncology for the Inquisitive Mind is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Oncology for the Inquisitive Mind hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Oncology for the Inquisitive Mind average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Oncology for the Inquisitive Mind's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 10 days ago.